Drug-resistance mechanisms and tuberculosis drugs

Claudio U. Köser*, Babak Javid, Kathleen Liddell, Matthew Ellington, Silke Feuerriegel, Stefan Niemann, Nicholas M. Brown, William J. Burman, Ibrahim Abubakar, Nazir A. Ismail, David Moore, Sharon Peacock, M. Estée Török

*Corresponding author for this work

Research output: Contribution to journalComment/debate

21 Citations (Scopus)
Original languageEnglish
Pages (from-to)305-307
Number of pages3
JournalThe Lancet
Volume385
Issue number9965
DOIs
Publication statusPublished - 24 Jan 2015

Bibliographical note

Funding Information:
This publication presents independent research supported by the Health Innovation Challenge Fund (HICF-T5-342 and WT098600), a parallel funding partnership between the UK Department of Health and Wellcome Trust. The views expressed in this publication are those of the authors and not necessarily those of the Department of Health, Public Health England, or the Wellcome Trust. CUK received travel expenses to a scientific meeting from Janssen. CUK, SN, and SJP are collaborating with the TB Alliance and Otsuka Pharmaceutical to test the in-vitro potency of delamanid, PA-824, and TBA-354. BJ is a Tsinghua-Janssen Scholar. MJE was funded by Bruker Daltonics to attend a conference. NMB is a consultant for Discuva Ltd, was funded by Astellas Pharma Ltd to attend a conference, and is the President of the British Society for Antimicrobial Chemotherapy. WJB chairs the Data and Safety Monitoring Boards for clinical trials of bedaquiline. SJP has received funding for travel and accommodation from Illumina Inc. MET was funded by Illumina Inc to attend a conference. KL, IA, NAI, and KL declare no competing interests.

Cite this